EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma

Anna Luise Grab, Peter S Kim, Lukas John iD, Kamlesh Bisht, Hongfang Wang, Anja Baumann, Helgi Van de Velde, Irene Sarkar iD, Debarati Shome, Philipp Reichert iD, Calin Manta, Stefanie Gryzik und 3 weitere

Cells · 20.05.2024 · 13 (10) · 879

DOI: 10.3390/cells13100879 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 20.05.2024. Verfasst von Anna Luise Grab und 14 weiteren Autor:innen. Beteiligte Einrichtung: Heidelberg Myeloma Center, Department of Medicine V, Medical Faculty Heidelberg and University Hospital, Heidelberg University, Im Neuenheimer Feld 4…. Hauptthemen laut MEDLINE: ADP-ribosyl Cyclase 1, Antibodies, Bispecific, Multiple Myeloma, T-Lymphocytes. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Flagship initiative for engineering molecular systems, University Heidelberg, Germany, Sanofi, Excellence Strategy of the Flagship Initiative Engineering Molecular Systems (University Heidelberg, Germany).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current treatment strategies for multiple myeloma (MM) are highly effective, but most patients develop relapsed/refractory disease (RRMM). The anti-CD38/CD3xCD28 trispecific antibody SAR442257 targets CD38 and CD28 on MM cells and co-stimulates CD3 and CD28 on T cells (TCs). We evaluated different key aspects such as MM cells and T cells avidity interaction, tumor killing, and biomarkers for drug potency in three distinct cohorts of RRMM patients. We found that a significantly higher proportion of RRMM patients (86%) exhibited aberrant co-expression of CD28 compared to newly diagnosed MM (NDMM) patients (19%). Furthermore, SAR442257 mediated significantly higher TC activation, resulting in enhanced MM killing compared to bispecific functional knockout controls for all relapse cohorts (Pearson’s r = 0.7). Finally, patients refractory to anti-CD38 therapy had higher levels of TGF-β (up to 20-fold) compared to other cohorts. This can limit the activity of SAR442257. Vactoserib, a TGF-β inhibitor, was able to mitigate this effect and restore sensitivity to SAR442257 in these experiments. In conclusion, SAR442257 has high potential for enhancing TC cytotoxicity by co-targeting CD38 and CD28 on MM and CD3/CD28 on T cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ADP-ribosyl Cyclase 1Antibodies, BispecificMultiple MyelomaT-LymphocytesHumansCD28 AntigensCD3 ComplexCell Line, TumorMembrane GlycoproteinsRecurrence

Stichwörter der Autor:innen

T cell engagercell aviditymicroenvironmentrefractory multiple myeloma

Substanzen

ADP-ribosyl Cyclase 1Antibodies, BispecificCD28 AntigensCD3 ComplexCD38 protein, humanMembrane Glycoproteins

Autor:innen und Institutionen

  • Heidelberg Myeloma Center, Department of Medicine V, Medical Faculty Heidelberg and University Hospital, Heidelberg University, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany.
  • Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
  • Sanofi Research and Development, Sanofi North America, Cambridge, MA 02141, USA.
  • LUMICKS, 1059 CM Amsterdam, The Netherlands.
  • GMMG Central Study Lab, Biobank, University Hospital Heidelberg, 69120 Heidelberg, Germany.

ORCID-Profile: Lukas John, Irene Sarkar, Philipp Reichert

Förderung

  • Flagship initiative for engineering molecular systems, University Heidelberg, Germany
  • Sanofi
  • Excellence Strategy of the Flagship Initiative Engineering Molecular Systems (University Heidelberg, Germany)
  • Dietmar-Hopp Foundation

Zitieren

APA

Grab, A. L., Kim, P. S., John, L., Bisht, K., Wang, H., Baumann, A., Van de Velde, H., Sarkar, I., Shome, D., Reichert, P., Manta, C., Gryzik, S., Reijmers, R. M., Weinhold, N., & Raab, M. S. (2024). Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma. Cells, 13(10), 879. https://doi.org/10.3390/cells13100879

Vancouver

Grab AL, Kim PS, John L, Bisht K, Wang H, Baumann A, et al. Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma. Cells. 2024;13(10):879. doi:10.3390/cells13100879

BibTeX
@article{Grab2024,
  author = {Grab, Anna Luise and Kim, Peter S and John, Lukas and Bisht, Kamlesh and Wang, Hongfang and Baumann, Anja and Van de Velde, Helgi and Sarkar, Irene and Shome, Debarati and Reichert, Philipp and Manta, Calin and Gryzik, Stefanie and Reijmers, Rogier M and Weinhold, Niels and Raab, Marc S},
  title = {Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma},
  journal = {Cells},
  year = {2024},
  volume = {13},
  number = {10},
  pages = {879},
  doi = {10.3390/cells13100879}
}
Kostenlos starten →